CATEGORIES

Press Release

LATEST

TRENDING

EDITORS CHOICE

Benchmark KFF Survey: Annual Family Premiums for Employer Coverage Rise 7% to Nearly $24,000 in 2023

Amid Changing Abortion Laws, 1-in-10 Large Firms Say Their Largest Plan Doesn’t Cover Legally Provided Abortions Under Any Circumstances

FDA approves Ready-to-Use Ephedrine Injection, Emerphed™

Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

Opdivo® Approved for the Treatment of Advanced Esophageal Squamous Cell Carcinoma

FDA Approved Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel in ESCC Patients